2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
31
Recurrence
5
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Neoplasm, Residual
1
Myasthenia Gravis
1
Leukemia, Plasma Cell
1
Infections
1
Immunoglobulin Light-chain Amyloidosis
1
Cytokine Release Syndrome
1
Interventions
Rituximab
99
Cyclophosphamide
63
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
52
Mycophenolic Acid
34
Whole-Body Irradiation
33
Bortezomib
33
ibrutinib
29
Dexamethasone
27
Tacrolimus
26
Cyclosporine
25
Busulfan
23
Etoposide
22
Melphalan
20
Filgrastim
20
zanubrutinib
18
Methotrexate
18
Lenalidomide
18
Antilymphocyte Serum
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Sirolimus
13
Calcium Dobesilate
11
Flow Cytometry
10
Everolimus
10
venetoclax
9
ibritumomab tiuxetan
9
Prednisone
9
Indium
9
Cyclosporins
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
talquetamab
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled